VP Head of Therapeutics Design
Owns Evotec's in silico therapeutics design capability, uniting computational chemistry, generative and modality design (small molecules, peptides, protein engineering, degraders, molecular glues) and predictive ADMET/safety under one mandate. A newly created unit within the In Silico & AI group with an explicit build mandate: set technical vision, grow a multi-site team, and industrialise repeatable, benchmarked methods across partner programmes.
Evotec
Abingdon
On-site
Permanent